EAN 2021

I am a healthcare professional

Notice

Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.

Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.

By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.

Cookies

We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.

You can find out more about cookies by browsing our Privacy Policy.

I am a healthcare professional in the United States

Required field.

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

Medical Materials

Agenda

Coming soon

12:00 PM

Duration 3mins Virtual

Improvements in Work Productivity and Activity Impairment in OCR-treated patients with RRMS: 2-year CASTING study data

Comi G, Kister I, Van Wijmeersch B, Buffels R, Kuenzel T, Poloz Y, Vermersch P

Neuroscience | Multiple Sclerosis

01:00 PM

Duration 5mins Virtual

A Randomized, Double-Blind, Placebo-Controlled, Gene-Delivery Clinical Trial of rAAVrh74.MHCK7.micro-dystrophin for Duchenne Muscular Dystrophy

Jerry R Mendell; Perry B. Shieh; Zarife Sahenk; Kelly Lehman; Linda P Lowes; Natalie Reash; Megan Iammarino; Lindsay N Alfano; Jeremy D Woods; Christy L Skura; Howard C Mao; Loretta A Staudt; Rachael A Potter; Danielle Griffin; Sarah Lewis; Larry Hu; Sameer Upadhyay; Teji Singh; Louise R Rodino-Klapac

Neuroscience | Duchenne Muscular Dystrophy

05:00 PM

Duration 10mins Virtual

Safety of Ocrelizumab▼ in Patients With RRMS With Suboptimal Response to Prior DMTs: Data From the CASTING Study

Oreja-Guevara C, Wiendl H, Siva A, Kadner K, Kuenzel T, Buffels R, Vermersch P

Neuroscience | Multiple Sclerosis

05:30 PM

Duration 10mins Virtual

Effect of Ocrelizumab▼ on Cerebellar Atrophy in RMS and PPMS: Results from OPERA I/OPERA II and ORATORIO

Arnold DL, Assemlal HE, Traboulsee A, Kolind S, Sprenger T, Bar-Or A, Wolinksy J, Kappos L, Inglese M, Schneble HM, Magon S, Koendgen H, Bernasconi C, Gaetano L

Neuroscience | Multiple Sclerosis

01:15 PM

Duration 5mins Virtual

FIREFISH Parts 1 and 2: 24-Month safety and efficacy of risdiplam▼ in Type 1 SMA

Masson R, Boespflug-Tanguy O, Darras BT, Day JW, Deconinck N, Klein A, Mazurkiewicz-Bełdzińska M, Mercuri E, Rose K, Servais L, Vlodavets D, Xiong H, Zanoteli E, Dodman A, El-Khairi M, Gaki E, Gerber M, Gorni K, Kletzl H, Baranello G on behalf of the FIREFISH Working Group

Neuroscience | Spinal Muscular Atrophy

Duration 5mins Virtual

JEWELFISH: Safety and pharmacodynamic data in non-naïve patients with spinal muscular atrophy (SMA) receiving treatment with risdiplam▼

Bruno C, Chiriboga CA, Duong T, Fischer D, Kirschner J, Mercuri E, Gerber M, Gorni K, Kletzl H, Carruthers I, Scalco RS, Warren F, Muntoni F on behalf of the JEWELFISH Study Group

Neuroscience | Spinal Muscular Atrophy

Duration 5mins Virtual

RAINBOWFISH: A study of risdiplam▼ in newborns with presymptomatic spinal muscular atrophy (SMA)

Bertini E, Al-Muhaizea M, Farrar MA, Nelson L, Prufer A, Servais L, Wang Y, Zanoteli E, El-Khairi M, Gerber M, Gorni K, Kletzl H, Palfreeman L, Scalco RS, Finkel RS on behalf of the RAINBOWFISH Study Group

Neuroscience | Spinal Muscular Atrophy

Duration 5mins Virtual

Pooled Safety Data from the risdiplam▼ clinical trial development program

Servais L, Baranello G, Bertini E, Chiriboga CA, Darras BT, Day JW, Deconinck N, Fischer D, Goemans N, Kirschner J, Klein A, Masson R, Mazurkiewicz-Bełdzińska M, Wang Y, Bader-Weder S, Gorni K, Jaber B, McIver T, Scalco RS, Mercuri E on behalf of the FIREFISH, SUNFISH and JEWELFISH Study Groups

Neuroscience | Spinal Muscular Atrophy

03:15 PM

Duration 15mins Virtual

Roche Parkinson’s Disease Mobile Application v2 detects potential disease modifying effect of prasinezumab

Lipsmeier F, Taylor KI, Volkova-Volkmar E, Rukina D, Anzures-Cabrera J, Essioux L, Abt M, Lier B, Thomann AE, Svoboda H, Zago W, Pagano G, Postuma RB, Lindemann M

Neuroscience | Parkinson's Disease

03:45 PM

Duration 15mins Virtual

A Phase II study to evaluate the safety and efficacy of prasinezumab in early Parkinson's disease (PASADENA): Results from Part 1 Week 52

Pagano G, Taylor KI, Anzures-Cabrera J, Marchesi M, Zago W, Tripuraneni R, Boulay A, Vogt A, Boess FG, Nikolcheva T, Svoboda H, Britschgi M, Lipsmeier F, Lindemann M, Dziadek S, Azulay J, Mollenhauer B, Lopez Manzanares L, Russell DS, Boyd JT, Nicholas AP, Luquin MR, Hauser RA, Simuni TS, Gasser T, Poewe W, Kinney GG, Doody R, Fontoura P, Umbricht D, and Bonni A for the PASADENA Investigators and Prasinezumab Study Group

Neuroscience | Parkinson's Disease

06:15 PM

Duration 15mins Virtual

Reliability and validity of passively measured gait, gestures from smartphones and smartwatches in Parkinson’s disease

Volkova-Volkmar E, Thomann AE, Lipsmeier F, Taylor KI, Postuma RB, Cheng W, Lier B, Trundell D, Zago W, Boulay A, Pagano G, Gossens C, Lindemann M

Neuroscience | Parkinson's Disease

04:45 PM

Duration 10mins Virtual

Satralizumab in patients with neuromyelitis optica spectrum disorder (NMOSD) and concomitant autoimmune disease (CAID)

Anthony Traboulsee, Michael R. Yeaman, Brian G. Weinshenker, Jacqueline Palace, Ingo Kleiter, Xiujing Kou, Daniela Stokmaier, Kristina Weber, Kazuo Fujihara, Takashi Yamamura

Neuroscience | Neuromyelitis Optica

Duration 10mins Virtual

Efficacy and safety of satralizumab in adults with AQP4-IgG-seropositive neuromyelitis optica spectrum disorder (NMOSD): Results from the phase 3 SAkura studies

Jeffrey L. Bennett, Edward Fox, Benjamin Greenberg, Brian G. Weinshenker, Kathleen Blondeau, Kristina Weber, Shervin Gholizadeh, Daniela Stokmaier, H.-Christian von Büdingen, Anthony Traboulsee

Neuroscience | Neuromyelitis Optica

05:00 PM

Duration 10mins Virtual

SUNFISH Part 2: 24-month efficacy and safety of risdiplam▼ in patients with Type 2 or non-ambulant Type 3 spinal muscular atrophy (SMA)

Nascimento A, Day JW, Deconinick N, Mazzone E, Oskoui M, Saito K, Vuillerot C, Baranello G, Boespflug-Tanguy O, Goemans N, Kirschner J, Kostera-Pruszcyck A, Servais L, Gerber M, Gorni K, Kletzl H, Martin C, Scalco RS, Staunton H, Yeung WY, Mercuri E on behalf of the SUNFISH working group

Neuroscience | Spinal Muscular Atrophy

08:30 AM

Duration 10mins Virtual

COVID-19 Risk Factors in People with Multiple Sclerosis Treated with Ocrelizumab▼

SL Hauser, R Gold, G Cutter, K Fitovski, HM Schneble, L Whitley, N Jessop, A Sauter

Neuroscience | Multiple Sclerosis

I am a healthcare professional

Notice

Cookies

External site

EAN 2021